Investigation into Immutep's Risk Disclosures
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 56 minutes ago
0mins
Source: Globenewswire
- Stock Price Plunge: Immutep's stock plummeted 83% to $0.48 per share following the March 13, 2026 announcement of the discontinuation of the TACTI-004 Phase III trial for futility, significantly undermining investor confidence and triggering a class action lawsuit.
- Legal Action Context: Levi & Korsinsky, LLP is examining the adequacy of Immutep's risk disclosures from March 24, 2025, to March 12, 2026, as investors who suffered losses due to inadequate disclosures may qualify for recovery.
- Insufficient Disclosure: The lawsuit alleges that Immutep failed to timely update investors on specific risks associated with internal clinical data, as management was aware of increased trial failure risks but continued to issue statements about
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.439
Low
12.00
Averages
12.00
High
12.00
Current: 0.439
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Immutep's Risk Disclosures
- Stock Price Plunge: Immutep's stock plummeted 83% to $0.48 per share following the March 13, 2026 announcement of the discontinuation of the TACTI-004 Phase III trial for futility, significantly undermining investor confidence and triggering a class action lawsuit.
- Legal Action Context: Levi & Korsinsky, LLP is examining the adequacy of Immutep's risk disclosures from March 24, 2025, to March 12, 2026, as investors who suffered losses due to inadequate disclosures may qualify for recovery.
- Insufficient Disclosure: The lawsuit alleges that Immutep failed to timely update investors on specific risks associated with internal clinical data, as management was aware of increased trial failure risks but continued to issue statements about
See More
Immutep Limited Faces Class Action Lawsuit for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Immutep Limited, alleging violations of federal securities laws affecting all investors who purchased securities between March 24, 2025, and March 12, 2026.
- False Statements Allegation: The complaint claims that the defendants concealed and misrepresented the status and prospects of the TACTI-004 trial, relying on positive results from other studies to suggest continued success, which severely undermined investor confidence in the company's future.
- Undisclosed Risks: Defendants were aware or recklessly disregarded the significantly increased risk of the TACTI-004 trial failing to meet its primary efficacy and safety endpoints, yet continued to issue false statements about the trial's “strong operational progress,” exacerbating investor losses.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by July 6, 2026, to seek compensation in the lawsuit, with the law firm offering services on a contingency fee basis, thereby reducing the financial burden on investors.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Immutep concealed negative information regarding the TACTI-004 trial, claiming strong progress while knowing the risks of failing to meet primary efficacy and safety endpoints, resulting in investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Immutep ADR Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, that they must apply to be lead plaintiffs by July 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's transparency regarding clinical trials.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its capability and experience in handling similar cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Lawsuit Background: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, concerning securities purchased between March 24, 2025, and March 12, 2026.
- False Statements: The complaint alleges that Immutep concealed the results of its TACTI-004 trial of eftilagimod alfa, as the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages, and the Schall Law Firm encourages affected investors to contact them before July 6, 2026, to participate in the lawsuit and seek recovery.
- Legal Proceedings: The class in this case has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their claims.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to seek compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information was disclosed, highlighting significant risks associated with the company's trial outcomes.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its extensive experience and success in this field.
- Investor Action Recommendation: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their interests and avoid inexperienced intermediaries.
See More
Investigation into Immutep's Risk Disclosures
- Stock Price Plunge: Immutep's stock plummeted 83% to $0.48 per share following the March 13, 2026 announcement of the discontinuation of the TACTI-004 Phase III trial for futility, significantly undermining investor confidence and triggering a class action lawsuit.
- Legal Action Context: Levi & Korsinsky, LLP is examining the adequacy of Immutep's risk disclosures from March 24, 2025, to March 12, 2026, as investors who suffered losses due to inadequate disclosures may qualify for recovery.
- Insufficient Disclosure: The lawsuit alleges that Immutep failed to timely update investors on specific risks associated with internal clinical data, as management was aware of increased trial failure risks but continued to issue statements about
See More
Immutep Limited Faces Class Action Lawsuit for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Immutep Limited, alleging violations of federal securities laws affecting all investors who purchased securities between March 24, 2025, and March 12, 2026.
- False Statements Allegation: The complaint claims that the defendants concealed and misrepresented the status and prospects of the TACTI-004 trial, relying on positive results from other studies to suggest continued success, which severely undermined investor confidence in the company's future.
- Undisclosed Risks: Defendants were aware or recklessly disregarded the significantly increased risk of the TACTI-004 trial failing to meet its primary efficacy and safety endpoints, yet continued to issue false statements about the trial's “strong operational progress,” exacerbating investor losses.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by July 6, 2026, to seek compensation in the lawsuit, with the law firm offering services on a contingency fee basis, thereby reducing the financial burden on investors.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Immutep concealed negative information regarding the TACTI-004 trial, claiming strong progress while knowing the risks of failing to meet primary efficacy and safety endpoints, resulting in investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Immutep ADR Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, that they must apply to be lead plaintiffs by July 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's transparency regarding clinical trials.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its capability and experience in handling similar cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Lawsuit Background: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, concerning securities purchased between March 24, 2025, and March 12, 2026.
- False Statements: The complaint alleges that Immutep concealed the results of its TACTI-004 trial of eftilagimod alfa, as the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages, and the Schall Law Firm encourages affected investors to contact them before July 6, 2026, to participate in the lawsuit and seek recovery.
- Legal Proceedings: The class in this case has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their claims.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to seek compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information was disclosed, highlighting significant risks associated with the company's trial outcomes.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its extensive experience and success in this field.
- Investor Action Recommendation: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their interests and avoid inexperienced intermediaries.
See More
